Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company that operates a contract development and manufacturing organization (CDMO) alongside an immunotherapy development platform, has entered into securities purchase and warrant inducement agreements with an existing institutional investor. The transaction is expected to generate approximately $4 million in aggregate gross proceeds, a capital infusion that matters because it provides the company with additional resources to grow its service business and continue developing its own drug candidates.
The private placement includes 2,458,334 American Depositary Shares (ADSs), or pre-funded warrants in lieu thereof, together with warrants to purchase up to 3,687,501 additional ADSs, at a combined purchase price of $1.20 per ADS and accompanying warrants. Separately, under the warrant inducement agreement, the investor will immediately exercise existing warrants covering 879,194 ADSs at a reduced exercise price of $1.20 per ADS and receive new warrants to purchase up to 1,318,791 ADSs. The newly issued Series A-1 warrants will be immediately exercisable at $1.20 per ADS and have five-year terms, giving the investor a long-dated stake in the company’s future. The transactions are expected to close on or about Oct. 15, 2026, subject to customary conditions, and A.G.P./Alliance Global Partners is serving as sole placement agent. For full details, the company directs readers to the complete press release at https://ibn.fm/eUtYO.
The implications of the announcement extend beyond the balance sheet. Scinai intends to use the net proceeds, together with existing cash resources, to expand its CDMO platform, advance customer programs and continue selective investment in its immunotherapy pipeline. That three-part allocation signals a dual strategy: scaling the fee-generating services arm while preserving optionality in proprietary research. Scinai owns Scinai Biopharma Services Ltd., a CDMO that provides development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel. Expanding that platform could help the company capture more outsourcing demand and build a steadier revenue base to support its therapeutic work. On the pipeline side, Scinai is advancing candidates licensed from the Max Planck Society and from PinCell S.r.l., and the new capital allows it to keep funding those programs selectively rather than pausing them.
For investors, the transaction also carries governance and dilution considerations. The warrant inducement reduces the exercise price on existing warrants to $1.20 per ADS, which may encourage the investor to convert rather than let the instruments expire, while the new Series A-1 warrants add potential future dilution if exercised. The reliance on an existing institutional investor, rather than a broad public offering, suggests continued support from a known backer but also concentrates influence. Market participants can follow the latest news and updates relating to SCNI in the company’s newsroom at https://ibn.fm/SCNI. The announcement was distributed through MissionIR, a communications platform within the Dynamic Brand Portfolio at IBN, which reaches investors through wire services such as InvestorWire and editorial syndication to 5,000+ outlets.
The closing remains subject to customary conditions, so the proceeds are not yet final. Still, the structure of the deal, with immediate exercise of existing warrants and new five-year warrants, points to a financing designed to deliver cash quickly while aligning the investor with a longer horizon. If completed as expected, the $4 million gives Scinai room to pursue CDMO expansion and pipeline investment at a time when biopharma companies are increasingly weighing service revenue against the high cost of drug development.
